EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Efficacy of Polynucleotides in Periorbital Rejuvenation: A Systematic Review

Rhea Ahuja, Samar Khalil, Hassan I Galadari, Stefania Guida

Aesthetic Surgery Journal Open Forum · 2026-01-14 · 8

DOI: 10.1093/asjof/ojag200 ↗
AbstractBibliografische Angaben

Abstract

Abstract Periorbital aging is characterized by dynamic wrinkles, volume loss, and dermal quality decline. Injectable polynucleotides (PNs) have emerged as biostimulatory agents for periorbital rejuvenation, and this review evaluates their efficacy and safety for this indication. The review was conducted per PRISMA 2020 guidelines and registered on PROSPERO (CRD420261288052). MEDLINE and Embase were searched from inception to January 30, 2026, for studies of adults receiving injectable PN for periorbital rejuvenation; no meta-analysis was performed given anticipated heterogeneity. Six studies (5 randomized split-face trials, 1 prospective case series; n = 350) met inclusion criteria, all conducted in Korean and Thai cohorts with Fitzpatrick III-V skin and predominantly middle-aged women (80%-100% female). Polynucleotide produced consistent short-term improvements in crow's feet severity and dermal quality metrics, with 40% to 70% of treated sides achieving at least a 1-grade Crow's Feet Grading Scale improvement at 12 weeks, reflecting cross-trial heterogeneity rather than a single pooled effect. In 2 trials (n = 30 and n = 215), PN was noninferior to polycaprolactone fillers for crow's feet correction; in 1 trial (n = 30), PN showed favorable biophysical outcomes relative to hyaluronic acid. Safety was favorable throughout, but no study followed patients beyond 6 months. In these East Asian, predominantly female cohorts, PN demonstrates short-term efficacy and a favorable safety profile through 6 months for periorbital rejuvenation. Given the small number of studies, heterogeneity, and lack of longer-term follow-up, findings should be regarded as preliminary. Generalization beyond the populations and timeframes studied awaits larger, longer-term, ethnically diverse trials with direct comparison to established modalities. Level of Evidence: 4 (Therapeutic)

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →